Ingmar Wahlqvist

Senior Director, New Ventures & Investments

2025 - Current

Managing the University's pre-seed investment fund, a joint initiative with Breakthrough Victoria, investing in university startups, and overseeing the University's growing portfolio of spinout companies.

Director

2024

Founded on diversity, Melbourne Forum is engaged group of people who come together to share ideas and perspectives on a range of local, national and global issues in a supportive and friendly environment. We organise bespoke opportunities for robust and interactive conversations. We invite eminent experts in different fields to lead a conversation, to inform us and invite us to think about, discuss and involve ourselves in social, economic, cultural, scientific, political and public policy issues of relevance to Melbourne. Melbourne Forum offers an opportunity to expand our thinking, hear different perspectives and identify ways we can contribute to important issues relevant to our City and us.

Director

2022

Perx is a digital health company enabling digital management of medically complex patients, increasing engagement with multiple aspects of their management, in turn delivering improved health and economic outcomes.

Director

2020

George Medicines commercializes the research of The George Institute for Global Health, one of the world’s leading health research institutes, to pursue the late-stage development of single-pill, multi-mechanism, combination therapies. It has successfully completed pivotal Phase 3 trials for its flagship GMRx2 product in hypertension and filed a New Drug Application with the FDA for registration in the US.

Director

2021 - 2024

PolyActiva uses polymer technology for extended-release delivery of medicine to the eye, with a primary focus on glaucoma.

Alternate Director

2011 - 2021

Director

2019 - 2024

Denteric is a spin-out company from CSL Ltd and the University of Melbourne. It is developing precision immunotherapies for chronic Porphyromonas gingivalis (Pg) infections, initially with a focus on severe periodontal disease. Its first product is a therapy designed to neutralise virulence factors (toxins) circulating in the blood that are produced by Pg.

Investment Manager / Senior Investment Manager

2009 - 2024

Brandon Capital Partners is a funds management business aiming to generate quality returns for Australia’s leading superannuation funds by investing in innovative life science ventures. The team works with entrepreneurs to build businesses, creating value for the entrepreneurs, their teams and our investors.

Director

2016 - 2021

Athena was a company investigating a speculative opportunity to treat autism with a naturally occurring but quite rare compound.

Director

2015 - 2020

Cardiora developed a medicine to treat heart failure. It manufactured GMP-grade product and conducted a series of successful trials.

Chairman

2015 - 2019

Director

2013 - 2019